drotaverine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
spasmolytics with a papaverine-like action 969 14009-24-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dihydroisoperparine
  • drotaverin hydrochloride
  • drotaverine hydrochloride
  • drotaverine HCl
  • drotaverine
  • drotaverin
  • isodihydroperparine
Hungarian drug; RN given refers to parent cpd; structure
  • Molecular weight: 397.52
  • Formula: C24H31NO4
  • CLOGP: 5.23
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 1
  • TPSA: 48.95
  • ALOGS: -5.30
  • ROTB: 9

Drug dosage:

DoseUnitRoute
0.10 g O
0.10 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 7.90 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 58 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.12 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9.30 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 13.75 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 61
kinase-selectivity-class AXL,BRAF,CAMK2D,DDR1,EPHB4,ERBB2,JAK1,MAP4K1,MAPK7,PDK4,SIK2,SIK3,STK33,TTK,ULK1 15
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Renal function test abnormal 162.49 85.53 34 1312 7157 90619944
Creatinine renal clearance increased 156.64 85.53 29 1317 3252 90623849
Sedation complication 128.57 85.53 33 1313 16911 90610190
Creatinine renal clearance decreased 120.22 85.53 32 1314 18867 90608234
Blood calcium decreased 105.40 85.53 32 1314 30150 90596951
Balance disorder 105.09 85.53 43 1303 97037 90530064
Multiple drug therapy 101.45 85.53 23 1323 6986 90620115
Drug abuse 97.79 85.53 39 1307 82308 90544793
Orthostatic hypotension 95.13 85.53 32 1314 41795 90585306
Sedation 90.70 85.53 32 1314 48139 90578962
Cognitive disorder 89.84 85.53 35 1311 69372 90557729

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Renal function test abnormal 153.89 53.38 34 1663 8912 110578690
Creatinine renal clearance increased 152.74 53.38 29 1668 3596 110584006
Sedation complication 122.23 53.38 33 1664 19822 110567780
Creatinine renal clearance decreased 114.56 53.38 32 1665 21783 110565819
Blood calcium decreased 98.88 53.38 32 1665 35813 110551789
Multiple drug therapy 97.60 53.38 23 1674 7991 110579611
Balance disorder 96.02 53.38 43 1654 116517 110471085
Cognitive disorder 80.80 53.38 35 1662 87476 110500126
Orthostatic hypotension 79.68 53.38 32 1665 66217 110521385
Sedation 78.11 53.38 32 1665 69651 110517951
Drug interaction 76.08 53.38 62 1635 500121 110087481
Drug abuse 67.93 53.38 39 1658 177372 110410230
Depressed level of consciousness 63.49 53.38 32 1665 112246 110475356
Toxicity to various agents 57.54 53.38 52 1645 480503 110107099
Overdose 55.62 53.38 38 1659 233756 110353846
Constipation 53.51 53.38 44 1653 357742 110229860

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A03AD02 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Papaverine and derivatives
MeSH PA D000700 Analgesics
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D014665 Vasodilator Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents

Related Drugs by ATC class:

A03AD Papaverine and derivatives 2 drugs
moxaverinepapaverine

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.16 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
cAMP-specific 3',5'-cyclic phosphodiesterase 4B Enzyme WOMBAT-PK
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel WOMBAT-PK

External reference:

IDSource
D07088 KEGG_DRUG
985-12-6 SECONDARY_CAS_RN
C0058762 UMLSCUI
CHEBI:135630 CHEBI
CHEMBL551978 ChEMBL_ID
DB06751 DRUGBANK_ID
1712095 PUBCHEM_CID
C005317 MESH_SUPPLEMENTAL_RECORD_UI
2239 INN_ID
98QS4N58TW UNII
23684 RXNORM
007309 NDDF
007310 NDDF
1173005008 SNOMEDCT_US
1173007000 SNOMEDCT_US
719933003 SNOMEDCT_US

Pharmaceutical products:

None